ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
18 oct. 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177Lu)Companies enter into an additional manufacturing and supply...
ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
23 avr. 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
A Novel Therapeutic Approach to Treatment using ITM-31 Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University...
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
30 janv. 2024 07h00 HE
|
ITM Isotope Technologies Munich SE
GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9),...
ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference
21 déc. 2023 08h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, December 21, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster and CFO, Dr. Klaus...
ITM to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 10h30 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, January 03, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO Steffen Schuster and CFO Dr. Klaus Maleck will...
ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
21 juil. 2022 05h21 HE
|
ITM Isotope Technologies Munich SE
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive...
ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope
21 juin 2022 11h45 HE
|
ITM Isotope Technologies Munich SE
First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale production of medical isotopes for cancer therapeutics ONTARIO, CANADA, and MUNICH, GERMANY – June...
ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress
15 juin 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, June 15, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will host an industry-sponsored lunch symposium on...
Gentex Wins 2020 Automotive News PACE Award for Its Integrated Toll Module
29 avr. 2020 10h00 HE
|
Gentex Corporation
ZEELAND, Mich., April 29, 2020 (GLOBE NEWSWIRE) -- Gentex Corporation, a leading supplier of digital vision, connected car, dimmable glass and fire protection technologies, was named a 2020...
Michael Lee-Chin joins the ITM Supervisory Board
06 juin 2019 11h52 HE
|
Portland Holdings Inc.
BURLINGTON, Ontario, June 06, 2019 (GLOBE NEWSWIRE) -- Portland Holdings is pleased to announce that Michael Lee-Chin has been appointed to the supervisory board of ITM Isotopen Technologien München...